CCL11 as a cancer target: molecular role and the mechanisms for potential therapeutic intervention

CCL11 (eotaxin-1) is dysregulated across human cancers and linked to proliferation, invasion, angiogenesis and metastatic niche formation. Its biology is more complex than that of a single oncogenic ligand, and whether and how to drug it remains unresolved.

We frame CCL11 as a multi-receptor, double-edged cancer target. Beyond CCR3, it acts as an agonist at CCR5 and an antagonist or weak partial agonist at CCR2, while ACKR1 and ACKR2 buffer the free ligand pool. The axis is pro-tumorigenic through tumor-cell, stromal and myeloid routes, yet tumor-suppressive when CCR3 on eosinophils drives antitumour activity; its net direction must therefore be established before a modality is selected. We grade each receptor-cell pairing by level of evidence, separating demonstrated effects from those extrapolated from receptor-sharing ligands, and assess four intervention layers against the redundancy, buffering and on-target liabilities that constrain translation.

Targeting CCL11 requires triage: the rational modality depends on the validated direction of the axis, the dominant receptor-cell pairing, and whether signaling should be blocked or augmented. The near-term opportunity lies in repurposing de-risked receptor antagonists, particularly maraviroc, in biomarker-guided combinations. No trial has demonstrated CCL11 dependence, so the axis is best pursued through its receptors.